In vivo 17β-estradiol treatment contributes to podocyte actin stabilization in female db/db mice

Paola Catanuto, Alessia Fornoni, Simone Pereira-Simon, Fayi Wu, Kerry L. Burnstein, Xiaomei Xia, Francesco Conti, Andrea Lenzi, Sharon Elliot

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

We recently showed that 17β-estradiol (E2) treatment ameliorated type 2 diabetic glomerulosclerosis in mice in part by protecting podocyte structure and function. Progressive podocyte damage is characterized by foot process effacement, vacuolization, detachment of podocytes from the glomerular basement membrane, and apoptosis. In addition, podocytes are highly dependent on the preservation of their actin cytoskeleton to ensure proper function and survival. Because E2 administration prevented podocyte damage in our study on diabetic db/db mice and has been shown to regulate both actin cytoskeleton and apoptosis in other cell types and tissues, we investigated whether actin remodeling and apoptosis were prevented in podocytes isolated from E2-treated diabetic db/db mice. We performed G-actin/F-actin assays, Western analysis for Hsp25 expression, Ras-related C3 botulinum toxin substrate 1 (Rac1) activity, and apoptosis assays on previously characterized podocytes isolated from both in vivo-treated placebo and E2 female db/db mice. We found that in vivo E2 protects against a phenotype change in the cultured podocytes characterized by a percent increase of F-actin vs. G-actin, suppression of Hsp25 expression and transcriptional activation, increase of Rac1 activity, and decreased apoptotic intermediates. We conclude from these studies that E2 treatment protects against podocyte damage and may prevent/reduce diabetes-induced kidney disease.

Original languageEnglish (US)
Pages (from-to)5888-5895
Number of pages8
JournalEndocrinology
Volume153
Issue number12
DOIs
StatePublished - Dec 1 2012

    Fingerprint

ASJC Scopus subject areas

  • Endocrinology

Cite this